Annexon (ANNX) Amortization of Deferred Charges (2021 - 2026)
Annexon's (ANNX) quarterly Amortization of Deferred Charges came in at $418000.0 in Q1 2026, up 16.43% year-on-year from $359000.0 in Q1 2025, and up 3.98% quarter-over-quarter from $402000.0 in Q4 2025.
Annexon (ANNX) Amortization of Deferred Charges (2021 - 2026) Analysis & Trends
Annexon's Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at $418000.0 for Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges rose 16.43% year-over-year to $418000.0 in Q1 2026; TTM through Mar 2026 was $1.6 million, a 16.53% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, up 16.56% from the prior year.
- Amortization of Deferred Charges climbed to $418000.0 in Q1 2026 per ANNX's latest filing, from $402000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $488000.0 in Q4 2022 and bottomed at $230000.0 in Q1 2022.
- The 5-year median for Amortization of Deferred Charges is $319000.0 (2024), against an average of $327411.8.
- Biggest YoY gain for Amortization of Deferred Charges was 69.12% in 2022; the steepest drop was 40.38% in 2022.
- Year by year, Amortization of Deferred Charges stood at $488000.0 in 2022, then sank by 39.34% to $296000.0 in 2023, then rose by 16.55% to $345000.0 in 2024, then increased by 16.52% to $402000.0 in 2025, then gained by 3.98% to $418000.0 in 2026.
- Per Business Quant, the three latest ANNX Amortization of Deferred Charges figures stand at $418000.0 (Q1 2026), $402000.0 (Q4 2025), and $387000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - |
| 2 | Nanobiotix | 1,905.61 Bn | 1,905.55 Bn | - |
| 3 | Akari Therapeutics | 1,011.81 Bn | 1,011.81 Bn | - |
| 4 | BeOne Medicines | 467.29 Bn | 462.50 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.89 Bn | 115.65 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.64 Bn | 34.63 Bn | 959.66 Mn |
| 10 | Annexon | 1.02 Bn | 1.02 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 418,000.00 |
| Mar 31, 2026 | 418,000.00 |
| Dec 31, 2025 | 402,000.00 |
| Dec 31, 2025 | 402,000.00 |
| Sep 30, 2025 | 387,000.00 |
| Sep 30, 2025 | 387,000.00 |
| Jun 30, 2025 | 372,000.00 |
| Jun 30, 2025 | 372,000.00 |
| Mar 31, 2025 | 359,000.00 |
| Mar 31, 2025 | 359,000.00 |
| Dec 31, 2024 | 345,000.00 |
| Dec 31, 2024 | 345,000.00 |
| Sep 30, 2024 | 332,000.00 |
| Sep 30, 2024 | 332,000.00 |
| Jun 30, 2024 | 319,000.00 |
| Jun 30, 2024 | 319,000.00 |
| Mar 31, 2024 | 308,000.00 |
| Mar 31, 2024 | 308,000.00 |
| Dec 31, 2023 | 296,000.00 |
| Dec 31, 2023 | 296,000.00 |